OmniAb (OABI) Other Non-Current Liabilities (2021 - 2026)
OmniAb (OABI) posted quarterly Other Non-Current Liabilities of $75000.0 for Q1 2026, down 14.77% year-over-year from $88000.0 in Q1 2025, and down 3.85% quarter-over-quarter from $78000.0 in Q4 2025.
OmniAb (OABI) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Other Non-Current Liabilities for 6 consecutive years, with $75000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 14.77% year-over-year to $75000.0; the TTM figure through Mar 2026 stood at $75000.0 (down 14.77% YoY), while the FY2025 annual figure was $78000.0, down 9.3% from the prior year.
- Other Non-Current Liabilities retreated to $75000.0 in Q1 2026 per OABI's latest filing, from $78000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $3.5 million in Q3 2023 and bottomed at $31000.0 in Q1 2024.
- Historically, Other Non-Current Liabilities has averaged $772571.4 across 5 years, with a median of $78000.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities sank 99.05% — and 2023, when it surged 6863.04%.
- OmniAb's Other Non-Current Liabilities stood at $46000.0 in 2022, then soared by 6863.04% to $3.2 million in 2023, then slumped by 97.32% to $86000.0 in 2024, then retreated by 9.3% to $78000.0 in 2025, then decreased by 3.85% to $75000.0 in 2026.
- Business Quant data shows OABI's Other Non-Current Liabilities at $75000.0 in Q1 2026, $78000.0 in Q4 2025, and $79000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 965,000.00 |
| Mar 31, 2026 | 75,000.00 |
| Dec 31, 2025 | 78,000.00 |
| Sep 30, 2025 | 79,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | 86,000.00 |
| Sep 30, 2024 | 53,000.00 |
| Jun 30, 2024 | 52,000.00 |
| Mar 31, 2024 | 31,000.00 |
| Dec 31, 2023 | 3.20 Mn |
| Sep 30, 2023 | 3.52 Mn |
| Jun 30, 2023 | 3.38 Mn |
| Mar 31, 2023 | 44,000.00 |
| Dec 31, 2022 | 46,000.00 |
| Dec 31, 2021 | 4.83 Mn |